The impact of chemo-induced menopause on the quality of life of young women with non-metastatic breast cancer in Algeria Original article
Article Sidebar
Main Article Content
Abstract
Background: Breast cancer is the most common cancer in females worldwide. Young women with breast cancer are treated with chemotherapy, which may exhibit gonadotoxicity thus inducing chemo- induced menopause with a risk of deterioration in their quality of life.
Method: A prospective study first of its kind in Algeria was carried out on 57 patients aged between 30 and 49 years that went for consultation at the oncology department of Pierre and Marie Curie Medical Centre Algiers. The medical files obtained and criteria of questionnaires: Quality of Life Questionnaire for Breast Cancer (QLQ-BR23) and the Quality of Life Questionnaire-Core 30 (QLQ-C30) were used to assess the quality of life in patients.
Results: From the medical files, patients had a dominant histological type of invasive ductal carcinoma at 96% and Scarff-Bloom-Richardson (SBR) II grade and luminal B profile were the most frequent. The (QLQ-C30) having averages of global health status, symptom score, and functional score with 56.34, 63.7, and 45.75 respectively. QLQ-BR23 having averages for symptom, functional score of 61.6 and 49.71 respectively.
Conclusion: Chemotherapy induces gonadotoxicity, which results in chemo-induced menopause that has a negative impact on the quality of life of young women. QLQ-BR23 is more suitable than QLQ-C30 to access the context of this study.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Cathcart-Rake EJ, Ruddy KJ, Bleyer A et al. Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. JCO Oncol Pract. 2021; 17: 305-13.
3. Hamdan D, Nguyen TT, Leboeuf C et al. Genomics applied to the treatment of breast cancer. Oncotarget. 2019; 10: 4786-801.
4. Gabriel CA, Domchek SM. Breast cancer in young women. Breast Cancer Res. 2010; 12: 212.Lutchman Singh K, Muttukrishna S, Stein RC et al. Predictors of ovarian reserve in young women with breast cancer. Br J Cancer. 2007; 96: 1808-16.
5. Wenners A, Grambach J, Koss J et al. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial. BMC Cancer. 2017; 17: 632.
6. Anderson RA, Su HI. The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer. Front Endocrinol. 2020; 11: 574263.
7. Bjelic-Radisic V, Cardoso F, Cameron D et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol. 2020; 31: 283-8.
8. Kaasa S, Bjordal K, Aaronson N et al. The EORTC Core Quality of Life Questionnaire (QLQ-C30): Validity and Reliability When Analysed With Patients Treated With Palliative Radiotherapy. Eur J Cancer. 1995; 31A(13-14): 2260-3.
9. Jahanmohan JP. Les cancers du sein agressifs: conséquences de la ménopause chimio-induite chez les femmes jeunes atteintes d’un cancer du sein non métastatique et facteurs pronostiques de la rechute du cancer du sein triple négatif. 177.
10. Anderson RA, Mansi J, Coleman RE et al. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017; 87: 58-64.